Literature DB >> 12030945

Review article: Helicobacter pylori "rescue" regimen when proton pump inhibitor-based triple therapies fail.

J P Gisbert1, J M Pajares.   

Abstract

Even with the currently most effective treatment regimens, about 10-20% of patients will fail to obtain eradication of Helicobacter pylori infection. Therefore, in designing a treatment strategy, we should not focus on the results of primary therapy alone, but also on the final (overall) eradication rate. The choice of second-line treatment depends on which treatment was used initially, as re-treatment with the same regimen is not recommended. Therefore, it is not necessary to perform culture after the first eradication failure. Assessment of the sensitivity of H. pylori to antibiotics only after failure of the second treatment is suggested in clinical practice. Different possibilities of empirical treatment have been suggested. After failure of proton pump inhibitor-amoxicillin-clarithromycin, quadruple therapy has generally been used. More recently, replacement of the proton pump inhibitor and the bismuth compound by ranitidine bismuth citrate has also achieved good results. After proton pump inhibitor-amoxicillin-nitroimidazole failure, re-treatment with proton pump inhibitor-amoxicillin-clarithromycin has been proven to be effective. Finally, first-line treatment should not combine clarithromycin and metronidazole in the same regimen, because of the problem of resistance to both antibiotics. Recently, rifabutin-based rescue therapies have been shown to constitute an encouraging strategy for eradication failures, as they are effective against H. pylori strains resistant to antibiotics.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12030945     DOI: 10.1046/j.1365-2036.2002.01276.x

Source DB:  PubMed          Journal:  Aliment Pharmacol Ther        ISSN: 0269-2813            Impact factor:   8.171


  41 in total

1.  Rescue therapy using a rifabutin-based regimen is effective for cure of Helicobacter pylori infection.

Authors:  Sander Veldhuyzen van Zanten; Snehal Desai; Linda Best; Geraldine Cooper-Lesins; Dickran Malatjalian; David Haldane; Kevork Peltekian
Journal:  Can J Gastroenterol       Date:  2010-05       Impact factor: 3.522

2.  Second-line rescue therapy of helicobacter pylori infection.

Authors:  Javier P Gisbert
Journal:  Therap Adv Gastroenterol       Date:  2009-11       Impact factor: 4.409

Review 3.  "Rescue" regimens after Helicobacter pylori treatment failure.

Authors:  Javier P Gisbert
Journal:  World J Gastroenterol       Date:  2008-09-21       Impact factor: 5.742

4.  Third-line rescue therapy with bismuth-containing quadruple regimen after failure of two treatments (with clarithromycin and levofloxacin) for H. pylori infection.

Authors:  J P Gisbert; A Perez-Aisa; L Rodrigo; J Molina-Infante; I Modolell; F Bermejo; M Castro-Fernández; R Antón; B Sacristán; A Cosme; J Barrio; Y Harb; M Gonzalez-Barcenas; M Fernandez-Bermejo; A Algaba; A C Marín; A G McNicholl
Journal:  Dig Dis Sci       Date:  2013-10-15       Impact factor: 3.199

5.  Second-line and third-line trial for helicobacter pylori infection in patients with duodenal ulcers: A prospective, crossover, controlled study.

Authors:  György M Buzás; Hajnalka Györffy; Ilona Széles; Anna Szentmihályi
Journal:  Curr Ther Res Clin Exp       Date:  2004-01

6.  Advantages of Moxifloxacin and Levofloxacin-based triple therapy for second-line treatments of persistent Helicobacter pylori infection: a meta analysis.

Authors:  Yuqin Li; Xiayue Huang; Linhua Yao; Ruihua Shi; Guoxin Zhang
Journal:  Wien Klin Wochenschr       Date:  2010-07-16       Impact factor: 1.704

Review 7.  Third-line rescue therapy for Helicobacter pylori infection.

Authors:  Rossella Cianci; Massimo Montalto; Franco Pandolfi; Giovan-Battista Gasbarrini; Giovanni Cammarota
Journal:  World J Gastroenterol       Date:  2006-04-21       Impact factor: 5.742

8.  [Clinical practice guideline on the management of patients with dyspepsia. Update 2012].

Authors:  Javier P Gisbert; Xavier Calvet; Juan Ferrándiz; Juan Mascort; Pablo Alonso-Coello; Mercè Marzo
Journal:  Aten Primaria       Date:  2012-10-01       Impact factor: 1.137

Review 9.  Blue light for infectious diseases: Propionibacterium acnes, Helicobacter pylori, and beyond?

Authors:  Tianhong Dai; Asheesh Gupta; Clinton K Murray; Mark S Vrahas; George P Tegos; Michael R Hamblin
Journal:  Drug Resist Updat       Date:  2012-07-28       Impact factor: 18.500

10.  Expression, purification, crystallization and preliminary X-ray analysis of an NAD-dependent glyceraldehyde-3-phosphate dehydrogenase from Helicobacter pylori.

Authors:  Paul R Elliott; Shabaz Mohammad; Helen J Melrose; Peter C E Moody
Journal:  Acta Crystallogr Sect F Struct Biol Cryst Commun       Date:  2008-07-26
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.